MUTANTS OF ANTI-CD40 ANTIBODY

摘要

It is intended to provide mutants of anti-CD40 antibody, which is expected a s therapeutically efficacious, having been optimized as a drug by lowering the ADCC and CDC activities thereof. Namely, an agonistic anti-CD40 monoclonal antibody mutant in which at least the hinge region is a hinge region originating in human IgG2 and which has a mutation and/or a substitution of one or more amino acids causing lowering in the ADCC and/or CDC activities i n the constant region; and an antagonistic anti-CD40 antibody mutant which has at least one mutation and/or substitution causing lowering in the ADCC and/o r CDC activities in the constant region.